期刊
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
卷 169, 期 -, 页码 241-255出版社
ELSEVIER
DOI: 10.1016/j.ejpb.2021.10.016
关键词
ADC; Cancer therapy; Metastatic breast cancer; TNBC; mAbs; Drug resistance
资金
- Fulbright, USA
Antibody-drug conjugate-based therapy combines the high specificity of antibodies with the strong potency of payloads, showing potential efficacy in breast cancer treatment. Despite the challenge of ADC resistance, several ADC therapies have shown progress in cancer treatment.
Antibody-drug conjugate-based therapy for treatment of cancer has attracted much attention because of its enhanced efficacy against numerous cancer types. Commonly, an ADC includes a mAb linked to a therapeutic payload. Antibody, linker and payload are the three main components of ADCs. The high specificity of antibodies is integrated with the strong potency of payloads in ADCs. ADCs with potential cytotoxic small molecules as payloads, generate antibody-mediated cancer therapy. Recently, ADCs with DNA-damaging agents have shown favor over microtubule-targeting agents as payloads. Although ADC resistance can be a barrier to effectiveness, several ADC therapies have been either approved or are in clinical trials for cancer treatment. The ADC-based treatments of breast cancers, particularly TNBC, MDR and metastatic breast cancers, have shown promise in recent years. This review discusses ADC drug designs, and developed for different types of breast cancer including TNBC, MDR and metastatic breast cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据